|
1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27(5): 1047–53. 2. Lazar MA. How obesity causes diabetes: not a tall tale. Science 2005; 307 (5708): 373–5. 3. Ruchat SM, Rankinen T, Weisnagel SJ, Rice T, Rao DC, Bergman RN, et al. Improvements in glucose homeostasis in response to regular exercise are influenced by PPARG Pro12Ala variant: results from the HERITAGE Family Study. Diabetologia 2010; 53(4): 679-89. 4. Samson S. Role of Wnt signaling and TCF7L2 for beta cell function and regeneration in mouse models of diabetes. Baylor College of Medicine, Houston, Texas. 2011. 5. Villareal DT, Robertson H, Bell GI, Patterson BW, Tran H, Wice B, et al. TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action. Diabetes 2010; 59(2): 479–85. 6. Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006; 38(3): 320–3. 7. Cauchi S, El Achhab Y, Choquet H, Dina C, Krempler F, Weitgasser R, et al. TCF7L2 is reproducibly associated with type 2 diabetes in various ethnic groups: a global metaanalysis. J Mol Med 2007; 85(7): 777–82. 8. Yi F, Brubaker PL, Jin T. TCF-4 mediates cell type-specific regulation of proglucagon gene expression by _-catenin and glycogen synthase kinase-3ß. J Biol Chem 2005; 280(2): 1457–64. 9. Kovacs P, Berndt J, Ruschke K, Klöting N, Schön MR, Körner A, et al. TCF7L2 gene expression in human visceral and subcutaneous adipose tissue is differentially regulated but not associated with type 2 diabetes mellitus. Metabolism 2008; 57(9): 1227-31. 10. Lyssenko V, Lupi R, Marchetti P, Del-Guerra S, Orho-Melander M, Almgren P, et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 2004; 117(8): 2155–63. 11. Elbein SC, Chu WS, Das SK, Yao-Borengasser A, Hasstedt SJ, Wang H, et al. Transcription factor 7-like 2 polymorphisms and type 2 diabetes, glucose homeostasis traits and gene expression in US participants of European and African descent. Diabetologia 2007; 50(8): 1621-30. 12. Palizban A, Nikpour M, Salehi R, Maracy MR. Association of a common variant in TCF7L2 gene with type 2 diabetes mellitus in a Persian population. Clin Exp Med 2012; 12(2): 115-9. 13. Amoli MM, Amiri P, Tavakkoly-Bazzaz J, Charmchi E, Hafeziyeh J, Keramatipour M, et al. Replication of TCF7L2 rs7903146 association with type 2 diabetes in an Iranian population. Genetics Molecular Biol 2010; 33(3): 449-51. 14. Abedi B, Abbasi-Bakhtiari R. The effect of a 12-week combined training program on serum leptin, C- reactive protein and the insulin resistance index in overweight men. Feyz 2015; 19(4): 292-300. [in Persian] 15. Malekyian-Fini E, Kaviani-Nia A, Mahmoudi F. The interactive effect of aerobic training and resveratrol supplementation on C-reactive protein and metabolic profiles in women with type 2 diabetes. Feyz 2015; 19(5): 372-81. [in Persian] 16. McCaffery JM, Jablonski KA, Franks PW, Dagogo-Jack S, Wing RR, Knowler WC, et al. TCF7L2 Polymorphism, Weight Loss and Proinsulin: Insulin Ratio in the Diabetes Prevention Program. PLoS One 2011; 6(7): e21518. 17. Eizadi M, Behboudi L, Zahedmanesh F, Afsharmand Z. Effect of Acute and Chronic Exercise on Beta-Cell Function in Diabetic Patients. Knowledge Health 2012; 6(4): 15-19. 18. Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403. 19. Garrow JS. Obesity: definition, Aetiology and Assessment. Encyclopedia Human Nutrition. Academic Press 1999: 1430-34. 20. Coughlin CC, Finck BN, Eagon JC, Halpin VJ, Magkos F, Mohammed BS, et al. Effect of marked weight loss on adiponectin gene expression and plasma concentrations. Obesity (Silver Spring) 2007; 15(3): 640-5. 21. Malin SK, Solomon TP, Blaszczak A, Finnegan S, Filion J, Kirwan JP. Pancreatic β-cell function increases in a linear dose-response manner following exercise training in adults with prediabetes. Am J Physiol Endocrinol Metab 2013; 305(10): 1248-54. 22. Madsen SM, Thorup AC, Overgaard K, Jeppesen PB. High Intensity Interval Training Improves Glycaemic Control and Pancreatic β Cell Function of Type 2 Diabetes Patients. PLoS One 2015; 10(8): e0133286. 23. Krotkiewski M, Lo¨nnroth P, Mandroukas K, Wroblewski Z, Rebuffe´-Scrive M, Holm G, et al. The effects of physical training on insulin secretion and effectiveness and on glucose metabolism in obesity and type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1985; 28(12): 881–90, 1985. 24. Whyte LJ, Ferguson C, Wilson J, Scott RA, Gill JM. Effects of single bout of very high-intensity exercise on metabolic health biomarkers in overweight/obese sedentarymen. Metabolism 2013; 62(2): 212–9. 25. Whyte LJ, Gill JM, Cathcart AJ. Effect of 2 weeks of sprint interval training on health-related outcomes in sedentary overweight/obese men. Metabolism 2010; 59(10): 1421–8. 26. AbouAssi H, Slentz CA, Mikus CR, Tanner CJ, Bateman LA, Willis LH, et al. The effects of aerobic, resistance, and combination training on insulin sensitivity and secretion in overweight adults from STRRIDE AT/RT: a randomized trial. J Appl Physiol (1985) 2015; 118(12): 1474-82. 27. Lyssenko V, Jonsson A, Almgren P, Pulizzi N, Isomaa B, Tuomi T, et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 2008; 359(21): 2220–32. 28. Schäfer SA, Machicao F, Fritsche A, Häring HU, Kantartzis K. New type 2 diabetes risk genes provide new insights in insulin secretion mechanisms. Diabetes Res Clin Pract 2011; 93 Suppl 1: 9-24. 29. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344(18): 1343–50. 30. Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–40. 31. Boule´ NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glyce- mic control and body mass in type 2 diabetes mellitus: a meta-analysis of con- trolled clinical trials. JAMA 286(10): 1218–27. 32. Church TS, Cheng YJ, Earnest CP, Barlow CE, Gibbons LW, Priest EL, Blair SN: Ex- ercise capacity and body composition as predictors of mortality among men with diabetes. Diabetes Care 2004; 27(1): 83–8. 33. Wei M, Gibbons LW, Kampert JB, Nicha- man MZ, Blair SN. Low cardiorespiratory fitness and physical inactivity as predic- tors of mortality in men with type 2 diabe- tes. Ann Intern Med 2000; 132(8): 605–11. 34. Zachwieja JJ, Toffolo G, Cobelli C, Bier DM, Yarasheski KE. Resistance exercise and growth hormone administration in older men: effects on insulin sensitivity and secretion during a stable-label intra- venous glucose tolerance test. Metabolism 199; 45(2): 254 –60. 35. Ivy JL. Role of exercise training in the pre- vention and treatment of insulin resis- tance and non-insulin-dependent diabetes mellitus. Sports Med 1997; 24(5): 321–37. 36. Slentz CA, Tanner CJ, Bateman LA, Durheim MT, Huffman KM, Houmard JA, et al. Effect of exercise training intensity on pancreatic Beta cell function. Diabetes Care 2009; 32(10): 1807-11. 37. Oliveira CA, Paiva MF, Mota CA, Ribeiro C, Leme JA, Luciano E, et al. Exercise at anaerobic threshold intensity and insulin secretion by isolated pancreatic islets of rats. Islets 2010; 2(4): 240-6. 38. Huang HH, Farmer K, Windscheffel J, Yost K, Power M, Wright DE, et al. Exercise increases insu- lin content and basal secretion in pancreatic islets in type 1 diabetic mice. Exp Diabetes Res 2011; 2011: 481427. 39. Almeida FN, Proença AR, Chimin P, Marçal AC, Bessa-Lima F, Carvalho CR. Physical exercise and pancreatic islets :acute and chronic actions on insulin secretion. Islets 2012; 4(4): 296-301. 40. Weedon MN. The importance of TCF7L2. Diabet Med 2007; 24(10): 1062–6. 41. Schäfer SA, Tschritter O, Machicao F, Thamer C, Stefan N, Gallwitz B, et al. Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. Diabetologia 2007; 50(12): 2443–50. 42. da Silva Xavier G, Loder MK, McDonald A, Tarasov AI, Carzaniga R, Kronenberger K, et al. TCF7L2 regulates late events in insulin secretion from pancreatic islet-cells. Diabetes 2009; 58(4): 894–905. 43. Loos RJ, Franks PW, Francis RW, Barroso I, Gribble FM, Savage DB, et al. TCF7L2 polymorphisms modulate proinsu- lin levels and -cell function in a British europid population. Diabetes 2007; 56(7): 1943–7. 44. Kirchhoff K, Machicao F, Haupt A, Schafer SA, Tschritter O, Staiger H, et al. Polymorphisms in the TCF7L2, CDKAL1 and SLC30A8 genes are associated with impaired proinsulin conversion. Diabetologia 2008; 51(4): 597–601 45. Stolerman ES, Manning AK, McAteer JB, Fox CS, Dupuis J, Meigs JB, et al. TCF7L2 variants are associated with increased proinsulin/ insulin ratios but not obesity traits in the Framingham Heart Study. Diabetologia 2009; 52(4): 614–20. 46. Loder MK, da Silva Xavier G, McDonald A, Rutter GA. TCF7L2 controls insulin gene expression and insulin secretion i n mature pancreatic β-cells. Biochem Soc Trans 2008; 36 (Pt 3): 357-9.
|
.png)
.png){kind=logo}
